Admin Core
管理核心
基本信息
- 批准号:9916575
- 负责人:
- 金额:$ 17.84万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-01 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:Advisory CommitteesAntiviral AgentsBiologicalBotanical dietary supplementsBotanicalsCollaborationsCommunicationConsultationsDevelopmentEnsureEnvironmentEvaluationFellowshipFutureGoalsHumanHuman ResourcesImmuneInternationalIntervention StudiesJournalsLegal patentMississippiMonitorNatural ProductsOutcomePeer ReviewPoliciesPositioning AttributePostdoctoral FellowPrincipal InvestigatorPropertyPublicationsRegulationResearchResearch PersonnelResearch Project GrantsResourcesSpirulina preparationStructureSupervisionTimeTrainingUnited States National Institutes of HealthUniversitiesUpdateVirus Diseasesauthoritycareercareer developmentdata sharing networksdesignexperienceflexibilitygraduate studentmeetingsoral supplementationprogramsresiliencesymposiumsynergismtraining opportunityweb site
项目摘要
ADMINISTRATIVE CORE: SUMMARY/ABSTRACT
The overall objective of the proposed University of Mississippi (UM) Botanical Dietary Supplements Research
Center (BDSRC) is to generate the necessary information that will provide the scientific rationale to optimize
the design of future human intervention studies to evaluate the use of Spirulina-derived oral supplements in
promoting antiviral resilience. To help achieve this goal the Administrative Core will oversee and coordinate
research efforts among the UM BDSRC components – a Botanical Core and two research projects. The
Program Director and leader of the Administrative Core, Dr. Ikhlas Khan, is an internationally recognized
expert in the field of natural products and brings two decades of experience successfully managing multi-
faceted botanical research programs. Serving as Associate Director of both the UM BDSRC and the
Administrative Core will be Dr. Nirmal Pugh. Dr. Pugh has a strong background in the biological evaluation of
immune-enhancing botanicals, with an emphasis on Spirulina, and has well-established, collaborative
relationships with the leader of the Botanical Core and the principal investigators of the two research projects.
Our first aim is to implement a flexible and responsive governance structure to manage, coordinate and
supervise all UM BDSRC activities, monitor progress through well-defined milestones, and realign UM BDSRC
resources as needed to best meet the needs of its investigators. Expected outcomes include (1)
commencement of monthly meetings of the Internal Steering Committee; (2) establishment of an External
Advisory Committee; (3) compliance with policies and regulations; and (4) oversight of progress and
establishment of clear lines of authority and responsibility within the UM BDSRC. Our second aim is to promote
communication, collaboration, and dissemination of UM BDSRC research and findings. Expected outcomes
include (1) development and timely updates of a website dedicated to the UM BDSRC, and (2) exploration of
possible collaborations with other BDSRCs and CARBON components. Our third aim is to provide an
environment suitable for training opportunities and oversee career development initiatives for post-doctoral
fellows and graduate students. Expected outcomes include establishing competitive fellowships and
participation in conferences/training courses within the UM BDSRC.
管理核心:总结/摘要
拟议的密西西比大学(UM)植物性膳食补充剂研究的总体目标
中心(BDSRC)的任务是生成必要的信息,为优化提供科学依据。
设计未来的人类干预研究,以评估螺旋藻衍生口服补充剂的使用
促进抗病毒能力。为了帮助实现这一目标,行政核心将监督和协调
研究工作之间的UM BDSRC组件-植物核心和两个研究项目。的
项目主任兼行政核心领导人Ikhlas Khan博士是国际公认的
天然产品领域的专家,并带来了二十年的经验,成功地管理多个,
多方面的植物学研究项目。担任UM BDSRC和
行政核心是尼尔马尔·皮尤医生。Pugh博士在生物学评价方面有很强的背景,
免疫增强植物药,重点是螺旋藻,并已建立良好的,合作
与植物核心的领导人和两个研究项目的主要研究人员的关系。
我们的第一个目标是实施一个灵活和反应迅速的治理结构,以管理、协调和
监督所有UM BDSRC活动,通过明确的里程碑监控进度,并重新调整UM BDSRC
为最好地满足其调查人员的需要而提供的资源。预期成果包括(1)
* 开始举行内部指导委员会的每月会议; ⑵设立外部指导委员会,
(3)遵守政策及规例;及(4)监督进度及
在澳大BDSRC内建立明确的权力和责任界限。我们的第二个目标是促进
交流,合作和UM BDSRC研究和成果的传播。预期成果
包括(1)开发和及时更新专门用于UM BDSRC的网站,以及(2)探索
与其他BDSRC和CARBON组件的可能合作。我们的第三个目标是提供一个
环境适合培训机会,并监督博士后的职业发展计划
研究员和研究生。预期成果包括设立有竞争力的研究金,
参加UM BDSRC内的会议/培训课程。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ikhlas Ahmad Khan其他文献
Ikhlas Ahmad Khan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ikhlas Ahmad Khan', 18)}}的其他基金
Spirulina oral supplement for enhancing host resilience to virus infection
螺旋藻口服补充剂可增强宿主对病毒感染的抵抗力
- 批准号:
9916571 - 财政年份:2020
- 资助金额:
$ 17.84万 - 项目类别:
Spirulina oral supplement for enhancing host resilience to virus infection
螺旋藻口服补充剂可增强宿主对病毒感染的抵抗力
- 批准号:
10671056 - 财政年份:2020
- 资助金额:
$ 17.84万 - 项目类别:
Spirulina oral supplement for enhancing host resilience to virus infection
螺旋藻口服补充剂可增强宿主对病毒感染的抵抗力
- 批准号:
10200679 - 财政年份:2020
- 资助金额:
$ 17.84万 - 项目类别:
Spirulina oral supplement for enhancing host resilience to virus infection
螺旋藻口服补充剂可增强宿主对病毒感染的抵抗力
- 批准号:
10447026 - 财政年份:2020
- 资助金额:
$ 17.84万 - 项目类别:
Spirulina oral supplement for enhancing host resilience to virus infection
螺旋藻口服补充剂可增强宿主对病毒感染的抵抗力
- 批准号:
10683642 - 财政年份:2020
- 资助金额:
$ 17.84万 - 项目类别:
Science based authentication, validation & safety of botanical ingredients
基于科学的认证、验证
- 批准号:
10462606 - 财政年份:2011
- 资助金额:
$ 17.84万 - 项目类别:
Science Based Authentication of Dietary Supplements
基于科学的膳食补充剂认证
- 批准号:
8729317 - 财政年份:2011
- 资助金额:
$ 17.84万 - 项目类别:
相似海外基金
Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
- 批准号:
23K18186 - 财政年份:2023
- 资助金额:
$ 17.84万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
- 批准号:
10560883 - 财政年份:2023
- 资助金额:
$ 17.84万 - 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10730692 - 财政年份:2021
- 资助金额:
$ 17.84万 - 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
- 批准号:
21K06459 - 财政年份:2021
- 资助金额:
$ 17.84万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10189880 - 财政年份:2021
- 资助金额:
$ 17.84万 - 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
- 批准号:
2404261 - 财政年份:2020
- 资助金额:
$ 17.84万 - 项目类别:
Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10222540 - 财政年份:2020
- 资助金额:
$ 17.84万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10669717 - 财政年份:2020
- 资助金额:
$ 17.84万 - 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
- 批准号:
20K10713 - 财政年份:2020
- 资助金额:
$ 17.84万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10174522 - 财政年份:2020
- 资助金额:
$ 17.84万 - 项目类别:














{{item.name}}会员




